BioXcel Therapeutics BTAI Stock
BioXcel Therapeutics Price Chart
BioXcel Therapeutics BTAI Financial and Trading Overview
BioXcel Therapeutics stock price | 1.56 USD |
Previous Close | 21.28 USD |
Open | 21.25 USD |
Bid | 0 USD x 1200 |
Ask | 0 USD x 900 |
Day's Range | 20.74 - 22.06 USD |
52 Week Range | 9.17 - 34.13 USD |
Volume | 454.36K USD |
Avg. Volume | 568.64K USD |
Market Cap | 626.93M USD |
Beta (5Y Monthly) | 1.083802 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -23.51 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 53 USD |
BTAI Valuation Measures
Enterprise Value | 551.09M USD |
Trailing P/E | N/A |
Forward P/E | -4.1586075 |
PEG Ratio (5 yr expected) | -0.01 |
Price/Sales (ttm) | 1079.0558 |
Price/Book (mrq) | 11.8067 |
Enterprise Value/Revenue | 948.513 |
Enterprise Value/EBITDA | -3.078 |
Trading Information
BioXcel Therapeutics Stock Price History
Beta (5Y Monthly) | 1.083802 |
52-Week Change | 108.13% |
S&P500 52-Week Change | 20.43% |
52 Week High | 34.13 USD |
52 Week Low | 9.17 USD |
50-Day Moving Average | 21.81 USD |
200-Day Moving Average | 20.16 USD |
BTAI Share Statistics
Avg. Volume (3 month) | 568.64K USD |
Avg. Daily Volume (10-Days) | 521.21K USD |
Shares Outstanding | 29.16M |
Float | 18.23M |
Short Ratio | 5.97 |
% Held by Insiders | 31.26% |
% Held by Institutions | 53.55% |
Shares Short | 3.72M |
Short % of Float | 50.22% |
Short % of Shares Outstanding | 12.77% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -30871.42% |
Gross Margin | 95.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -57.31% |
Return on Equity (ttm) | -151.46% |
Income Statement
Revenue (ttm) | 581K USD |
Revenue Per Share (ttm) | 0.02 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 355K USD |
EBITDA | -179032992 USD |
Net Income Avi to Common (ttm) | -187080992 USD |
Diluted EPS (ttm) | -7.28 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 165.52M USD |
Total Cash Per Share (mrq) | 5.68 USD |
Total Debt (mrq) | 96.09M USD |
Total Debt/Equity (mrq) | 181.29 USD |
Current Ratio (mrq) | 6.164 |
Book Value Per Share (mrq) | 1.821 |
Cash Flow Statement
Operating Cash Flow (ttm) | -155280992 USD |
Levered Free Cash Flow (ttm) | -91326000 USD |
Profile of BioXcel Therapeutics
Country | United States |
State | CT |
City | New Haven |
Address | 555 Long Wharf Drive |
ZIP | 06511 |
Phone | 475 238 6837 |
Website | https://www.bioxceltherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 183 |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of rare forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Q&A For BioXcel Therapeutics Stock
What is a current BTAI stock price?
BioXcel Therapeutics BTAI stock price today per share is 1.56 USD.
How to purchase BioXcel Therapeutics stock?
You can buy BTAI shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for BioXcel Therapeutics?
The stock symbol or ticker of BioXcel Therapeutics is BTAI.
Which industry does the BioXcel Therapeutics company belong to?
The BioXcel Therapeutics industry is Biotechnology.
How many shares does BioXcel Therapeutics have in circulation?
The max supply of BioXcel Therapeutics shares is 5.49M.
What is BioXcel Therapeutics Price to Earnings Ratio (PE Ratio)?
BioXcel Therapeutics PE Ratio is now.
What was BioXcel Therapeutics earnings per share over the trailing 12 months (TTM)?
BioXcel Therapeutics EPS is -23.51 USD over the trailing 12 months.
Which sector does the BioXcel Therapeutics company belong to?
The BioXcel Therapeutics sector is Healthcare.
BioXcel Therapeutics BTAI included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Capital Market Composite RCMP | 91.92 USD — |
-0.27
|
— — | 86.91 USD — | 95.14 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
- {{ link.label }} {{link}}